ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 088,24
0,89%
Dow Jones
38 239,66
0,40%
DAX
18 161,01
1,32%
Brent Oil
88,165
0,00%
Bitcoin
63 139,89
-0,94%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Arbutus Biopharma Corporation (ABUS)

  7. Arbutus Biopharma Corporation (ABUS) Actualités

ABUS Arbutus Biopharma Corporation

2,73
0,01 (0,37%)
26 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Arbutus Biopharma Corporation ABUS NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
0,01 0,37% 2,73 23:13:59
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
2,73 2,70 2,78 2,73 2,72
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
18/4/202413:30GLOBEArbutus to Report First Quarter 2024 Financial Results and..
04/4/202414:30GLOBEArbutus Biopharma Announces Claim Construction Ruling in its..
08/3/202413:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
05/3/202422:48EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202413:31EDGAR2Form 8-K - Current report
29/2/202413:30GLOBEArbutus Reports Fourth Quarter and Year End 2023 Financial..
15/2/202413:30GLOBEArbutus to Report Fourth Quarter and Year End 2023 Financial..
14/2/202422:38EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14/2/202416:48EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202401:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/2/202401:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/1/202413:31EDGAR2Form 8-K - Current report
08/1/202413:30GLOBEArbutus Announces 2024 Corporate Objectives and Provides..
04/1/202422:09EDGAR2Form 8-K - Current report
21/11/202314:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
09/11/202322:02EDGAR2Form 8-K - Current report
08/11/202313:30GLOBEArbutus to Present at Jefferies London Healthcare Conference
07/11/202322:18EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
07/11/202313:31EDGAR2Form 8-K - Current report
07/11/202313:30GLOBEArbutus Reports Third Quarter 2023 Financial Results and..
07/11/202313:16EDGAR2Form 8-K - Current report
07/11/202313:15GLOBEArbutus Announces CEO, William Collier, to Retire December..
24/10/202313:30GLOBEArbutus to Report Third Quarter 2023 Financial Results and..
18/10/202313:30GLOBEArbutus to Present at H.C. Wainwright 4th Annual Hepatitis B..
11/10/202314:06EDGAR2Form 8-K - Current report
11/10/202314:05GLOBEArbutus Announces Multiple Abstracts Accepted for..
11/9/202323:07EDGAR2Form SC 13G - Statement of acquisition of beneficial..
11/9/202322:16EDGAR2Form 8-K - Current report
11/9/202322:15GLOBEArbutus Announces Pipeline Updates and Dosing of the First..
07/9/202313:30GLOBEArbutus to Participate in Two Upcoming Investor Conferences
03/8/202322:18EDGAR2Form S-8 - Securities to be offered to employees in employee..
03/8/202322:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
03/8/202313:31EDGAR2Form 8-K - Current report
03/8/202313:30GLOBEArbutus Reports Second Quarter 2023 Financial Results..
20/7/202313:30GLOBEArbutus to Report Second Quarter 2023 Financial Results and..
13/7/202322:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/7/202322:11EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/7/202322:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/7/202322:48EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/7/202322:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/7/202322:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/7/202313:31EDGAR2Form 8-K - Current report
12/7/202313:30GLOBEArbutus Appoints Melissa V. Rewolinski, PhD to its Board of..
10/7/202322:02EDGAR2Form 8-K - Current report
10/7/202322:01GLOBEArbutus Appoints Two New Executives
21/6/202313:30GLOBEArbutus Doses First Patient in Additional Treatment Arm of..
21/6/202308:01GLOBEArbutus Presents Preliminary AB-729 and Pegylated Interferon..
07/6/202308:01GLOBEArbutus to Present AB-729 and AB-836 Data at EASL Congress..

Dernières Valeurs Consultées

NASDAQ
ABUS
Arbutus Biopharma
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés